LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 38

Search options

  1. Article ; Online: Comparison of Interleukin-1 Ligand Expression by Human Papilloma Virus Status in HNSCCs.

    Khan, Ishrat Nourin / Gibson-Corley, Katherine N / Coppock, Joseph D / Simons, Andrean L

    Head and neck pathology

    2022  Volume 16, Issue 3, Page(s) 763–772

    Abstract: Interleukin-1 alpha (IL-1α) is a cytokine involved in the acute phase immune response and its expression is upregulated in a variety of solid tumors including head and neck squamous cell carcinomas (HNSCCs). Tumor expression of IL-1α is associated with ... ...

    Abstract Interleukin-1 alpha (IL-1α) is a cytokine involved in the acute phase immune response and its expression is upregulated in a variety of solid tumors including head and neck squamous cell carcinomas (HNSCCs). Tumor expression of IL-1α is associated with increased tumor aggressiveness in HNSCCs, but this has yet to be studied in the context of human papilloma virus (HPV) status. This study is aimed at determining differences in tumor expression and subcellular localization of IL-1α in HPV-positive (HPV+) and HPV-negative (HPV-) HNSCC tumors. Tissue microarrays (TMAs) containing HPV+ (n = 31) and HPV- (n = 47) primary and metastatic HNSCCs were analyzed for IL-1α expression using immunohistochemical (IHC) staining. HPV status was confirmed using p16 IHC staining and RNA in situ hybridization (RNA ISH). Differences in IL-1α protein expression and secretion in HPV+ and HPV- HNSCC cell lines were determined by western blot and ELISA respectively. Associations between tumor IL1A expression and survival outcomes were assessed in HPV+ and HPV- HNSCC patients from publicly available gene expression datasets. Tumor expression of IL-1α was significantly increased in HPV- tumors and cell lines (as detected by IHC and western blot respectively) compared to HPV+ tumors and cell lines. There was no difference in IL-1α release between HPV+ and HPV- cell lines. IL-1α was expressed in both nuclear and cytoplasmic compartments, with predominant expression in the nucleus. Gene expression of IL1A was significantly increased in HPV-tumors/cell lines compared to HPV+ tumors/cell lines. Lastly, increased IL1A gene expression was significantly associated with worse survival in HPV- tumors but not in HPV+ tumors. Overall IL-1α expression particularly in the nucleus may possess more prognostic significance in HPV- tumors rather than HPV+ tumors. This work warrants further investigation into the role of intracellular IL-1α ligand expression in HNSCCs and may have important implications in IL-1 pathway blockade as therapeutic strategy.
    MeSH term(s) Alphapapillomavirus ; Biomarkers, Tumor ; Carcinoma, Squamous Cell ; Head and Neck Neoplasms ; Humans ; Interleukin-1 ; Ligands ; Papillomaviridae ; Papillomavirus Infections ; RNA ; Squamous Cell Carcinoma of Head and Neck
    Chemical Substances Biomarkers, Tumor ; Interleukin-1 ; Ligands ; RNA (63231-63-0)
    Language English
    Publishing date 2022-03-25
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 2407834-7
    ISSN 1936-0568 ; 1936-055X
    ISSN (online) 1936-0568
    ISSN 1936-055X
    DOI 10.1007/s12105-022-01440-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Prognostic Role of Combined EGFR and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma.

    Wongpattaraworakul, Wattawan / Gibson-Corley, Katherine N / Choi, Allen / Buchakjian, Marisa R / Lanzel, Emily A / Rajan Kd, Anand / Simons, Andrean L

    Frontiers in oncology

    2022  Volume 12, Page(s) 885236

    Abstract: Background: Epidermal growth factor receptor (EGFR) is well known as a general prognostic biomarker for head and neck tumors, however the specific prognostic value of EGFR in oral squamous cell carcinoma (OSCC) is controversial. Recently, the presence ... ...

    Abstract Background: Epidermal growth factor receptor (EGFR) is well known as a general prognostic biomarker for head and neck tumors, however the specific prognostic value of EGFR in oral squamous cell carcinoma (OSCC) is controversial. Recently, the presence of tumor-infiltrating T cells has been associated with significant survival advantages in a variety of disease sites. The present study will determine if the inclusion of T cell specific markers (CD3, CD4 and CD8) would enhance the prognostic value of EGFR in OSCCs.
    Methods: Tissue microarrays containing 146 OSCC cases were analyzed for EGFR, CD3, CD4 and CD8 expression using immunohistochemical staining. EGFR and T cell expression scores were correlated with clinicopathological parameters and survival outcomes.
    Results: Results showed that EGFR expression had no impact on overall survival (OS), but EGFR-positive (EGFR+) OSCC patients demonstrated significantly worse progression free survival (PFS) compared to EGFR-negative (EGFR-) patients. Patients with CD3, CD4 and CD8-positive tumors had significantly better OS compared to CD3, CD4 and CD8-negative patients respectively, but no impact on PFS. Combined EGFR+/CD3+ expression was associated with cases with no nodal involvement and significantly more favorable OS compared to EGFR+/CD3- expression. CD3 expression had no impact on OS or PFS in EGFR- patients. Combinations of EGFR/CD8 and EGFR/CD4 expression showed no significant differences in OS or PFS among the expression groups.
    Conclusion: Altogether these results suggest that the expression of CD3+ tumor-infiltrating T cells can enhance the prognostic value of EGFR expression and warrants further investigation as prognostic biomarkers for OSCC.
    Language English
    Publishing date 2022-07-25
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.885236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles.

    Hasibuzzaman, M M / Ross, Kathleen A / Salem, Aliasger K / Narasimhan, Balaji / Simons, Andrean L

    Journal of visualized experiments : JoVE

    2021  , Issue 172

    Abstract: Cytokine therapy is a promising immunotherapeutic strategy that can produce robust antitumor immune responses in cancer patients. The proinflammatory cytokine interleukin-1 alpha (IL-1α) has been evaluated as an anticancer agent in several preclinical ... ...

    Abstract Cytokine therapy is a promising immunotherapeutic strategy that can produce robust antitumor immune responses in cancer patients. The proinflammatory cytokine interleukin-1 alpha (IL-1α) has been evaluated as an anticancer agent in several preclinical and clinical studies. However, dose-limiting toxicities, including flu-like symptoms and hypotension, have dampened the enthusiasm for this therapeutic strategy. Polyanhydride nanoparticle (NP)-based delivery of IL-1α would represent an effective approach in this context since this may allow for a slow and controlled release of IL-1α systemically while reducing toxic side effects. Here an analysis of the antitumor activity of IL-1α-loaded polyanhydride NPs in a head and neck squamous cell carcinoma (HNSCC) syngeneic mouse model is described. Murine oropharyngeal epithelial cells stably expressing HPV16 E6/E7 together with hRAS and luciferase (mEERL) cells were injected subcutaneously into the right flank of C57BL/6J mice. Once tumors reached 3-4 mm in any direction, a 1.5% IL-1a - loaded 20:80 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane:1,6-bis(p-carboxyphenoxy)hexane (CPTEG: CPH) nanoparticle (IL-1α-NP) formulation was administered to mice intraperitoneally. Tumor size and body weight were continuously measured until tumor size or weight loss reached euthanasia criteria. Blood samples were taken to evaluate antitumor immune responses by submandibular venipuncture, and inflammatory cytokines were measured through cytokine multiplex assays. Tumor and inguinal lymph nodes were resected and homogenized into a single-cell suspension to analyze various immune cells through multicolor flow cytometry. These standard methods will allow investigators to study the antitumor immune response and potential mechanism of immunostimulatory NPs and other immunotherapy agents for cancer treatment.
    MeSH term(s) Animals ; Head and Neck Neoplasms ; Humans ; Interleukin-1alpha ; Mice ; Mice, Inbred C57BL ; Nanoparticles ; Polyanhydrides
    Chemical Substances Interleukin-1alpha ; Polyanhydrides
    Language English
    Publishing date 2021-06-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Video-Audio Media
    ZDB-ID 2259946-0
    ISSN 1940-087X ; 1940-087X
    ISSN (online) 1940-087X
    ISSN 1940-087X
    DOI 10.3791/62683
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: In situ

    Cheng, Yinwen / Lemke-Miltner, Caitlin D / Wongpattaraworakul, Wattawan / Wang, Zhaoming / Chan, Carlos H F / Salem, Aliasger K / Weiner, George J / Simons, Andrean L

    Journal for immunotherapy of cancer

    2020  Volume 8, Issue 2

    Abstract: Background: CMP-001 is a novel Toll-like receptor-9 agonist that consists of an unmethylated CpG-A motif-rich G10 oligodeoxynucleotide (ODN) encapsulated in virus-like particles. : Methods: Immune cell activation in response to CMP-001±anti-Qβ was ... ...

    Abstract Background: CMP-001 is a novel Toll-like receptor-9 agonist that consists of an unmethylated CpG-A motif-rich G10 oligodeoxynucleotide (ODN) encapsulated in virus-like particles.
    Methods: Immune cell activation in response to CMP-001±anti-Qβ was performed using co-cultures of peripheral blood mononuclear cells and HPV+/HPV- HNSCC cells and then analyzed by flow cytometry.
    Results: Results showed that the activity of CMP-001 on immune cell (pDCs, monocytes, CD4+/CD8+ T cells and NK cells) activation depends on the presence of anti-Qβ. A 2-week 'priming' period after subcutaneous administration of CMP-001 was required for robust anti-Qβ development in mice.
    Conclusions: These results demonstrate that
    MeSH term(s) Animals ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; Cancer Vaccines/pharmacology ; Dendritic Cells/drug effects ; Dendritic Cells/immunology ; Drug Synergism ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Mice ; Mice, Inbred C57BL ; Oropharyngeal Neoplasms/drug therapy ; Oropharyngeal Neoplasms/immunology ; Programmed Cell Death 1 Receptor ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/immunology ; Toll-Like Receptor 9/agonists ; Toll-Like Receptor 9/immunology ; Vaccines, Virus-Like Particle/pharmacology
    Chemical Substances Cancer Vaccines ; Immune Checkpoint Inhibitors ; Programmed Cell Death 1 Receptor ; TLR9 protein, human ; Tlr9 protein, mouse ; Toll-Like Receptor 9 ; Vaccines, Virus-Like Particle
    Language English
    Publishing date 2020-10-15
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2020-000940
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model.

    Chitphet, Khanidtha / Geary, Sean M / Chan, Carlos H F / Simons, Andrean L / Weiner, George J / Salem, Aliasger K

    ACS biomaterials science & engineering

    2019  Volume 6, Issue 5, Page(s) 2659–2667

    Abstract: Doxorubicin (DOX) has been widely used for the treatment of various cancers, however, the use of soluble DOX is limited by its low therapeutic index and improved formulations are therefore sought. Aside from its tumoricidal properties, DOX has also been ... ...

    Abstract Doxorubicin (DOX) has been widely used for the treatment of various cancers, however, the use of soluble DOX is limited by its low therapeutic index and improved formulations are therefore sought. Aside from its tumoricidal properties, DOX has also been shown to cause an immunogenic form of cell death, however, it is becoming abundantly clear that in situ immune stimulation alone is insufficient to cause significant immune based antitumor activity and that immune checkpoint modulation is also required. In this study, DOX-loaded nanoparticles were made by nanoprecipitation of DOX with a PEGylated poly(lactide-
    MeSH term(s) Animals ; Cell Line, Tumor ; Doxorubicin ; Melanoma/drug therapy ; Mice ; Nanoparticles ; Polyethylene Glycols ; Polyglactin 910
    Chemical Substances Polyglactin 910 (34346-01-5) ; Polyethylene Glycols (3WJQ0SDW1A) ; Doxorubicin (80168379AG)
    Language English
    Publishing date 2019-12-20
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2373-9878
    ISSN (online) 2373-9878
    DOI 10.1021/acsbiomaterials.9b01108
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Impact of Nuclear Interleukin-1 Alpha and EGFR Expression on Recurrence and Survival Outcomes in Oral Squamous Cell Carcinomas.

    Rajan, Anand / Gibson-Corley, Katherine N / Choi, Allen B / Ofori-Amanfo, Georgina K / Ten Eyck, Patrick / Espinosa-Cotton, Madelyn / Sperry, Steven M / Simons, Andrean L

    Journal of oncology

    2019  Volume 2019, Page(s) 5859680

    Abstract: Interleukin-1 alpha (IL- ... ...

    Abstract Interleukin-1 alpha (IL-1
    Language English
    Publishing date 2019-06-19
    Publishing country Egypt
    Document type Journal Article
    ZDB-ID 2461349-6
    ISSN 1687-8469 ; 1687-8450
    ISSN (online) 1687-8469
    ISSN 1687-8450
    DOI 10.1155/2019/5859680
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent.

    Cheng, Yinwen / Borcherding, Nicholas / Ogunsakin, Ayomide / Lemke-Miltner, Caitlin D / Gibson-Corley, Katherine N / Rajan, Anand / Choi, Allen B / Wongpattaraworakul, Wattawan / Chan, Carlos H F / Salem, Aliasger K / Weiner, George J / Simons, Andrean L

    Scientific reports

    2021  Volume 11, Issue 1, Page(s) 1535

    Abstract: The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment natural killer (NK) and dendritic cell (DC) activity. The goal of this work is to examine the role of TLR8 expression/ ... ...

    Abstract The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment natural killer (NK) and dendritic cell (DC) activity. The goal of this work is to examine the role of TLR8 expression/activity in head and neck squamous cell carcinoma (HNSCC) to facilitate the prediction of responders to VTX-2337-based therapy. The prognostic role of TLR8 expression in HNSCC patients was assessed by TCGA and tissue microarray analyses. The anti-tumor effect of VTX-2337 was determined in SCCVII/C3H, mEERL/C57Bl/6 and TUBO-human EGFR/BALB/c syngeneic mouse models. The effect of combined VTX-2337 and cetuximab treatment on tumor growth, survival and immune cell recruitment was assessed. TLR8 expression was associated with CD8+ T cell infiltration and favorable survival outcomes. VTX-2337 delayed tumor growth in all 3 syngeneic mouse models and significantly increased the survival of cetuximab-treated mice. The anti-tumor effects of VTX-2337+ cetuximab were accompanied by increased splenic lymphoid DCs and IFNγ+ CD4+ and tumor-specific CD8+ T cells. Depletion of CD4+ T cells, CD8+ T cells and NK cells were all able to abolish the anti-tumor effect of VTX-2337+ cetuximab. Altogether, VTX-2337 remains promising as an adjuvant for cetuximab-based therapy however patients with high TLR8 expression may be more likely to derive benefit from this drug combination compared to patients with low TLR8 expression.
    MeSH term(s) Animals ; Antibody-Dependent Cell Cytotoxicity/immunology ; Antineoplastic Agents/pharmacology ; Benzazepines/metabolism ; Benzazepines/pharmacology ; Biomarkers, Pharmacological ; CD8-Positive T-Lymphocytes/immunology ; Cell Line, Tumor ; Cetuximab/metabolism ; Cetuximab/pharmacology ; Cytokines/metabolism ; Databases, Genetic ; Female ; Gene Expression/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Killer Cells, Natural/immunology ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C3H ; Mice, Inbred C57BL ; Neoplasms/drug therapy ; Neoplasms/immunology ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Toll-Like Receptor 8/drug effects ; Toll-Like Receptor 8/genetics ; Toll-Like Receptor 8/metabolism
    Chemical Substances Antineoplastic Agents ; Benzazepines ; Biomarkers, Pharmacological ; Cytokines ; TLR8 protein, human ; Toll-Like Receptor 8 ; VTX-2337 ; Cetuximab (PQX0D8J21J)
    Language English
    Publishing date 2021-01-15
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-020-80957-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent

    Yinwen Cheng / Nicholas Borcherding / Ayomide Ogunsakin / Caitlin D. Lemke-Miltner / Katherine N. Gibson-Corley / Anand Rajan / Allen B. Choi / Wattawan Wongpattaraworakul / Carlos H. F. Chan / Aliasger K. Salem / George J. Weiner / Andrean L. Simons

    Scientific Reports, Vol 11, Iss 1, Pp 1-

    2021  Volume 11

    Abstract: Abstract The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment natural killer (NK) and dendritic cell (DC) activity. The goal of this work is to examine the role of TLR8 ... ...

    Abstract Abstract The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment natural killer (NK) and dendritic cell (DC) activity. The goal of this work is to examine the role of TLR8 expression/activity in head and neck squamous cell carcinoma (HNSCC) to facilitate the prediction of responders to VTX-2337-based therapy. The prognostic role of TLR8 expression in HNSCC patients was assessed by TCGA and tissue microarray analyses. The anti-tumor effect of VTX-2337 was determined in SCCVII/C3H, mEERL/C57Bl/6 and TUBO-human EGFR/BALB/c syngeneic mouse models. The effect of combined VTX-2337 and cetuximab treatment on tumor growth, survival and immune cell recruitment was assessed. TLR8 expression was associated with CD8+ T cell infiltration and favorable survival outcomes. VTX-2337 delayed tumor growth in all 3 syngeneic mouse models and significantly increased the survival of cetuximab-treated mice. The anti-tumor effects of VTX-2337+ cetuximab were accompanied by increased splenic lymphoid DCs and IFNγ+ CD4+ and tumor-specific CD8+ T cells. Depletion of CD4+ T cells, CD8+ T cells and NK cells were all able to abolish the anti-tumor effect of VTX-2337+ cetuximab. Altogether, VTX-2337 remains promising as an adjuvant for cetuximab-based therapy however patients with high TLR8 expression may be more likely to derive benefit from this drug combination compared to patients with low TLR8 expression.
    Keywords Medicine ; R ; Science ; Q
    Subject code 616 ; 570
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Ketogenic Diet with Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma: Preclinical and Phase 1 Trial Results.

    Ma, Daniel C / Anderson, Carryn M / Rodman, Samuel N / Buranasudja, Visarut / McCormick, Michael L / Davis, Andrew / Loth, Elizabeth / Bodeker, Kellie L / Ahmann, Logan / Parkhurst, Jessica R / Sun, Wenqing / Follmer, Kayla R / Simons, Andrean L / Buatti, John M / Spitz, Douglas R / Fath, Melissa A / Allen, Bryan G

    Radiation research

    2021  Volume 196, Issue 2, Page(s) 213–224

    Abstract: Ketogenic diets (KD) are high in fat and low in carbohydrates, forcing cells to utilize mitochondrial fatty acid oxidation for energy production. Since cancer cells demonstrate increased mitochondrial oxidative stress relative to normal cells, we ... ...

    Abstract Ketogenic diets (KD) are high in fat and low in carbohydrates, forcing cells to utilize mitochondrial fatty acid oxidation for energy production. Since cancer cells demonstrate increased mitochondrial oxidative stress relative to normal cells, we hypothesized that a KD may selectively enhance metabolic oxidative stress in head and neck cancer cells, sensitizing them to radiation and platinum-based chemotherapy without causing increased toxicity in surrounding normal tissues. This hypothesis was tested in preclinical murine xenografts and in a phase 1 clinical trial (NCT01975766). In this study, mice bearing human head and neck cancer xenografts (FaDu) were fed either standard mouse chow or KetoCal® KD (90% fat, 8% carbohydrate, 2% protein) and exposed to ionizing radiation. Tumors were harvested from mice to test for glutathione, a biomarker of oxidative stress. In parallel, patients with locally advanced head and neck cancer were enrolled in a phase 1 clinical trial where they consumed KD and received radiation with concurrent platinum-based chemotherapy. Subjects consumed KetoCal KD via percutaneous endoscopic gastrostomy (PEG) tube and were also allowed to orally consume water, sugar-free drinks, and foods approved by a dietitian. Oxidative stress markers including protein carbonyls and total glutathione were assessed in patient blood samples both pre-KD and while consuming the KD. Mice bearing FaDu xenografts that received radiation and KD demonstrated a slight improvement in tumor growth rate and survival compared to mice that received radiation alone; however a variation in responses was seen dependent on the fatty acid composition of the diet. In the phase 1 clinical trial, a total of twelve patients were enrolled in the study. Four patients completed five weeks of the KD as per protocol (with variance in compliance). Eight patients did not tolerate the diet with concurrent radiation and platinum-chemotherapy (5 were patient decision and 3 were removed from study due to toxicity). The median number of days consuming a KD in patients who did not complete the study was 5.5 (range: 2-8 days). Reasons for discontinuation included "stress of diet compliance" (1 patient), grade 2 nausea (3 patients), and grade 3 fatigue (1 patient). Three patients were removed from the trial due to dose-limiting toxicities including: grade 4 hyperuricemia (2 patients) and grade 3 acute pancreatitis (1 patient). Median weight loss was 2.95% for the KD-tolerant group and 7.92% for patients who did not tolerate the diet. In conclusion, the ketogenic diet shows promise as a treatment combined with radiation in preclinical mouse head and neck cancer xenografts. A phase 1 clinical trial evaluating the safety and tolerability of KD demonstrated difficulty with diet compliance when combined with standard-of-care radiation therapy and cisplatin chemotherapy.
    MeSH term(s) 3-Hydroxyacyl CoA Dehydrogenases/drug effects ; 3-Hydroxyacyl CoA Dehydrogenases/radiation effects ; Acetyl-CoA C-Acyltransferase/drug effects ; Acetyl-CoA C-Acyltransferase/radiation effects ; Adult ; Aged ; Animals ; Carbon-Carbon Double Bond Isomerases/drug effects ; Carbon-Carbon Double Bond Isomerases/radiation effects ; Chemoradiotherapy/adverse effects ; Diet, Ketogenic/adverse effects ; Diet, Ketogenic/methods ; Enoyl-CoA Hydratase/drug effects ; Enoyl-CoA Hydratase/radiation effects ; Female ; Heterografts ; Humans ; Male ; Mice ; Middle Aged ; Mitochondria/drug effects ; Mitochondria/radiation effects ; Oxidative Stress/drug effects ; Oxidative Stress/radiation effects ; Racemases and Epimerases/drug effects ; Racemases and Epimerases/radiation effects ; Radiation, Ionizing ; Squamous Cell Carcinoma of Head and Neck/diet therapy ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/pathology ; Squamous Cell Carcinoma of Head and Neck/radiotherapy ; Stress, Physiological/drug effects ; Stress, Physiological/radiation effects
    Chemical Substances fatty acid oxidation complex ; 3-Hydroxyacyl CoA Dehydrogenases (EC 1.1.1.-) ; Acetyl-CoA C-Acyltransferase (EC 2.3.1.16) ; Enoyl-CoA Hydratase (EC 4.2.1.17) ; Racemases and Epimerases (EC 5.1.-) ; Carbon-Carbon Double Bond Isomerases (EC 5.3.3.-)
    Language English
    Publishing date 2021-06-02
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80322-4
    ISSN 1938-5404 ; 0033-7587
    ISSN (online) 1938-5404
    ISSN 0033-7587
    DOI 10.1667/RADE-20-00150.1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.

    Stanam, Aditya / Gibson-Corley, Katherine N / Love-Homan, Laurie / Ihejirika, Nnamdi / Simons, Andrean L

    Oncotarget

    2016  Volume 7, Issue 46, Page(s) 76087–76100

    Abstract: Erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly. To elucidate novel pathways involved in erlotinib ... ...

    Abstract Erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly. To elucidate novel pathways involved in erlotinib resistance, we compared the gene expression profiles of erlotinib-resistant (ER) vs. erlotinib-sensitive (ES) HNSCC cell lines. Enrichment analysis of microarray data revealed a deregulation of the IL-1 signaling pathway in ER versus ES-HNSCC cells. Gene expression of interleukin-1 alpha (IL1A) and interleukin-1 beta (IL1B) were significantly upregulated by > 2 fold in ER-SQ20B and ER-CAL 27 cells compared to their respective ES-cells. Secretion of the IL-1 receptor antagonist (IL-1RA) was significantly reduced in ER-cells compared to ES-cells. Blockade of IL-1 signaling using a recombinant IL-1R antagonist (anakinra) was able to inhibit the growth of ER-SQ20B and ER-CAL 27 but not ES-SQ20B and ES-CAL 27 xenografts as a single agent and in combination with erlotinib. ER-SQ20B xenografts treated with anakinra ± erlotinib were found to be less vascularized than ER-SQ20B xenografts treated with water or erlotinib. Mice bearing ER-SQ20B xenografts had significantly lesser circulating levels of G-CSF and IL-1β when treated with anakinra ± erlotinib compared to those treated with water or erlotinib alone. Furthermore, augmented mRNA levels of IL1A or interleukin-1 receptor accessory protein (IL1RAP) were associated with shortened survival in HNSCC patients. Altogether, blockade of the IL-1 pathway using anakinra overcame erlotinib resistance in HNSCC xenografts and may represent a novel strategy to overcome EGFR inhibitor resistance for treatment of HNSCC patients.
    MeSH term(s) Angiogenesis Inhibitors/pharmacology ; Animals ; Antineoplastic Agents/pharmacology ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/pathology ; Cell Line, Tumor ; Cell Survival/drug effects ; Cytokines/metabolism ; Disease Models, Animal ; Drug Resistance, Neoplasm/genetics ; Erlotinib Hydrochloride/pharmacology ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/genetics ; Head and Neck Neoplasms/metabolism ; Head and Neck Neoplasms/pathology ; Humans ; Inflammation Mediators/metabolism ; Interleukin 1 Receptor Antagonist Protein/pharmacology ; Interleukin-1/metabolism ; Mice ; Prognosis ; Protein Kinase Inhibitors/pharmacology ; Signal Transduction/drug effects ; Squamous Cell Carcinoma of Head and Neck ; Survival Analysis ; Transcriptome ; Xenograft Model Antitumor Assays
    Chemical Substances Angiogenesis Inhibitors ; Antineoplastic Agents ; Cytokines ; Inflammation Mediators ; Interleukin 1 Receptor Antagonist Protein ; Interleukin-1 ; Protein Kinase Inhibitors ; Erlotinib Hydrochloride (DA87705X9K)
    Language English
    Publishing date 2016-10-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.12590
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top